By Irwin Speizer
| Jeffrey Ubben: Value stocks plus activism is the strategy (Photographs by Thomas Borening) |
When ValueAct Capital, an $8 billion hedge fund firm in San Francisco, went scouting for investment targets a few years ago, it spotted Valeant Pharmaceuticals International, a Montreal-based drugmaker.
